PL2564202T3 - Sposoby wykrywania przeciwciał przeciw lekowi - Google Patents
Sposoby wykrywania przeciwciał przeciw lekowiInfo
- Publication number
- PL2564202T3 PL2564202T3 PL11716417T PL11716417T PL2564202T3 PL 2564202 T3 PL2564202 T3 PL 2564202T3 PL 11716417 T PL11716417 T PL 11716417T PL 11716417 T PL11716417 T PL 11716417T PL 2564202 T3 PL2564202 T3 PL 2564202T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- drug antibodies
- detecting anti
- detecting
- antibodies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32920110P | 2010-04-29 | 2010-04-29 | |
| EP10305455 | 2010-04-29 | ||
| PCT/EP2011/056732 WO2011135024A1 (en) | 2010-04-29 | 2011-04-28 | Methods for detecting antibodies |
| EP11716417.8A EP2564202B1 (en) | 2010-04-29 | 2011-04-28 | Methods for detecting anti-drug antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2564202T3 true PL2564202T3 (pl) | 2016-04-29 |
Family
ID=42246049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11716417T PL2564202T3 (pl) | 2010-04-29 | 2011-04-28 | Sposoby wykrywania przeciwciał przeciw lekowi |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9063151B2 (pl) |
| EP (1) | EP2564202B1 (pl) |
| JP (1) | JP2013527444A (pl) |
| KR (1) | KR20130100908A (pl) |
| CN (1) | CN102884433A (pl) |
| AU (1) | AU2011247610A1 (pl) |
| CA (1) | CA2795549A1 (pl) |
| CY (1) | CY1116719T1 (pl) |
| DK (1) | DK2564202T3 (pl) |
| ES (1) | ES2548533T3 (pl) |
| HR (1) | HRP20151023T1 (pl) |
| HU (1) | HUE027662T2 (pl) |
| IL (1) | IL222533A0 (pl) |
| PL (1) | PL2564202T3 (pl) |
| PT (1) | PT2564202E (pl) |
| RS (1) | RS54249B1 (pl) |
| SI (1) | SI2564202T1 (pl) |
| SM (1) | SMT201500233B (pl) |
| WO (1) | WO2011135024A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2564202T1 (sl) * | 2010-04-29 | 2015-12-31 | Theradiag Sa | Metode za odkrivanje protiteles proti zdravilu |
| BR112015012482A2 (pt) * | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
| EP3063543B1 (en) * | 2013-10-31 | 2020-03-11 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| DK3084439T3 (en) * | 2013-12-20 | 2018-12-03 | Phadia Ab | ANALYSIS OF ANTIBODIES |
| US9304657B2 (en) | 2013-12-31 | 2016-04-05 | Abbyy Development Llc | Audio tagging |
| WO2015166461A1 (en) * | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
| EP2982987A1 (en) | 2014-08-08 | 2016-02-10 | Proteomika, S.L. | Lateral flow immunoassays for the detection of antibodies against biological drugs |
| BR112017004810A2 (pt) | 2014-11-05 | 2017-12-12 | Hoffmann La Roche | imunoensaio |
| CN105277682A (zh) * | 2015-11-17 | 2016-01-27 | 苏州浩欧博生物医药有限公司 | 一种抗TNF-α单抗药物抗体检测试剂盒 |
| CN106093413A (zh) * | 2016-07-18 | 2016-11-09 | 本·沙朗 | 一种抗英夫利西抗体elisa检测试剂盒和检测方法 |
| KR20180052277A (ko) * | 2016-11-10 | 2018-05-18 | 가톨릭대학교 산학협력단 | 항-제9응고인자 항체의 검출 방법 및 검출 키트 |
| CN108535490A (zh) * | 2017-03-06 | 2018-09-14 | 苏州和锐生物科技有限公司 | 生物制剂血药浓度检测方法及试剂 |
| CN111133313A (zh) * | 2017-07-10 | 2020-05-08 | 拉姆巴姆医疗技术有限公司 | 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途 |
| IL277890B2 (en) * | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| EP3990922A1 (en) * | 2019-06-25 | 2022-05-04 | ProciseDx Inc. | Detection of anti-tnf alpha drug biologics and anti-drug antibodies |
| WO2023204378A1 (ko) * | 2022-04-19 | 2023-10-26 | 의료법인 성광의료재단 | 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004096274A1 (ja) | 2003-03-31 | 2006-07-13 | 協和醗酵工業株式会社 | 気道内投与剤 |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| CA2532556A1 (en) * | 2003-07-29 | 2005-02-24 | Genentech, Inc. | Assay for human anti cd20 antibodies and uses therefor |
| CN101371140B (zh) * | 2006-03-09 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 抗药物抗体的测定 |
| CN101506659B (zh) * | 2006-09-12 | 2012-12-12 | 弗·哈夫曼-拉罗切有限公司 | 抗药物抗体测定法 |
| WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
| CN101680880A (zh) | 2007-05-07 | 2010-03-24 | 惠氏公司 | 免疫检定中由抗碳水化合物抗体引起的干扰的消除 |
| US8227195B2 (en) * | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
| WO2009091240A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
| JP5634405B2 (ja) * | 2008-10-07 | 2014-12-03 | ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ | 試料中のアナライトの検出のための半逐次アッセイ |
| SI2564202T1 (sl) * | 2010-04-29 | 2015-12-31 | Theradiag Sa | Metode za odkrivanje protiteles proti zdravilu |
-
2011
- 2011-04-28 SI SI201130609T patent/SI2564202T1/sl unknown
- 2011-04-28 CA CA2795549A patent/CA2795549A1/en not_active Abandoned
- 2011-04-28 DK DK11716417.8T patent/DK2564202T3/en active
- 2011-04-28 JP JP2013506659A patent/JP2013527444A/ja active Pending
- 2011-04-28 WO PCT/EP2011/056732 patent/WO2011135024A1/en not_active Ceased
- 2011-04-28 CN CN2011800215050A patent/CN102884433A/zh active Pending
- 2011-04-28 ES ES11716417.8T patent/ES2548533T3/es active Active
- 2011-04-28 PL PL11716417T patent/PL2564202T3/pl unknown
- 2011-04-28 KR KR1020127031373A patent/KR20130100908A/ko not_active Ceased
- 2011-04-28 US US13/642,874 patent/US9063151B2/en active Active
- 2011-04-28 AU AU2011247610A patent/AU2011247610A1/en not_active Abandoned
- 2011-04-28 RS RS20150620A patent/RS54249B1/sr unknown
- 2011-04-28 EP EP11716417.8A patent/EP2564202B1/en active Active
- 2011-04-28 HR HRP20151023TT patent/HRP20151023T1/hr unknown
- 2011-04-28 HU HUE11716417A patent/HUE027662T2/en unknown
- 2011-04-28 PT PT117164178T patent/PT2564202E/pt unknown
-
2012
- 2012-10-18 IL IL222533A patent/IL222533A0/en unknown
-
2015
- 2015-06-22 US US14/745,765 patent/US9651560B2/en not_active Expired - Fee Related
- 2015-09-22 CY CY20151100826T patent/CY1116719T1/el unknown
- 2015-09-29 SM SM201500233T patent/SMT201500233B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE027662T2 (en) | 2016-10-28 |
| RS54249B1 (sr) | 2016-02-29 |
| EP2564202A1 (en) | 2013-03-06 |
| US9651560B2 (en) | 2017-05-16 |
| DK2564202T3 (en) | 2015-10-05 |
| US20130108631A1 (en) | 2013-05-02 |
| CA2795549A1 (en) | 2011-11-03 |
| SI2564202T1 (sl) | 2015-12-31 |
| AU2011247610A1 (en) | 2012-12-13 |
| US20150285815A1 (en) | 2015-10-08 |
| EP2564202B1 (en) | 2015-07-01 |
| US9063151B2 (en) | 2015-06-23 |
| WO2011135024A1 (en) | 2011-11-03 |
| SMT201500233B (it) | 2016-01-08 |
| PT2564202E (pt) | 2015-10-20 |
| CY1116719T1 (el) | 2017-03-15 |
| IL222533A0 (en) | 2012-12-31 |
| HRP20151023T1 (hr) | 2015-11-06 |
| JP2013527444A (ja) | 2013-06-27 |
| KR20130100908A (ko) | 2013-09-12 |
| CN102884433A (zh) | 2013-01-16 |
| ES2548533T3 (es) | 2015-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2564202T1 (sl) | Metode za odkrivanje protiteles proti zdravilu | |
| IL225534A0 (en) | A method for determining anti-drug isotope antibodies | |
| HUE039301T2 (hu) | Eljárás korai vonat-felismerésre | |
| GB201000467D0 (en) | Antibodies | |
| EP2569012A4 (en) | ANTI-FGFR2 ANTIBODY | |
| LT2530091T (lt) | Anti-dll3 antikūnas | |
| IL249501A0 (en) | A process for creating antibodies | |
| GB201011913D0 (en) | Detecting device | |
| ZA201404463B (en) | Detecting analytes | |
| SI3985979T1 (sl) | Metoda za določanje referenčne enote | |
| PL2542576T3 (pl) | Sposoby badań przesiewowych przeciwciał | |
| GB201002238D0 (en) | Antibodies | |
| EP2539469A4 (en) | METHOD FOR DETERMINING GENE NUTRITIONAL INTERACTIONS | |
| EP2579024A4 (en) | DEVICE FOR DETECTING BIOMOLECULES AND PROCESS FOR DETECTING BIOMOLECULES | |
| EP2587250A4 (en) | AUTOMATIC ANALYSIS DEVICE | |
| AP2013007021A0 (en) | Method for assaying hydrocarbons | |
| IL254651A0 (en) | Immunological determination method for the detection of thrombin | |
| PL2756306T3 (pl) | Sposób wykrywania antybiotyków | |
| EP2704123A4 (en) | OBJECT DETECTION DEVICE FOR VEHICLE | |
| GB2468023B (en) | Seismic attributes for structural analysis | |
| PL2753928T3 (pl) | Kompozycje i sposoby wykrywania autoprzeciwciał | |
| GB2488612B (en) | Device for sensitivity testing | |
| HK1188288A (en) | Methods for determining anti-drug antibody isotypes | |
| GB201005177D0 (en) | Detecting analytes | |
| PL390760A1 (pl) | Urządzenie do wykrywania obecności elektrolitu |